← Leaderboards
Mark K. Greenwald
Wayne State University
$16,108,394
Attributed
$25,816,087
Total exposure
14
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,816,087 · 13
SAMHSA$0 · 1
By mechanism
R01$9,299,214 · 4
UG3$6,654,182 · 1
U01$4,021,723 · 1
R33$3,515,464 · 2
R21$981,147 · 2
R34$684,027 · 1
Top collaborators
- Cynthia L Arfken5 shared
- Scott James Peltier5 shared
- Jon-Kar Zubieta5 shared
- Erin F Madden3 shared
- Roberto Ciccocioppo2 shared
- Alana C. Conti2 shared
- Joseph Grieco2 shared
- David M Ledgerwood2 shared
Most similar at Wayne State University
Same institution · by research overlap
- Leonard Lipovich$2,603,000
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsBasePlacebosDoseResponseVolunteerOpioidProceduresPlacebo ControlEvaluationPublic Health Medicine (Field)BehavioralBuprenorphineTreatment OutcomeAddictionLaboratoriesCravingElasticitySamplingFutureDrug UsageEconomicsMethodologyPrice
Grant awards (46)
TRAIN@wayne: Translational Research in Addiction and Integrative Neuroscience$213,768
T32 · FY2025 · DA · contact PI
Development of cebranopadol, a potent dual MOP/NOP agonist, for the treatment of Opioid Use Disorder (OUD)$3,324,591
UG3 · FY2024 · DA
TRAIN@wayne: Translational Research in Addiction and Integrative Neuroscience$238,968
T32 · FY2024 · DA · contact PI
Development of cebranopadol, a potent dual MOP/NOP agonist, for the treatment of Opioid Use Disorder (OUD)$3,329,591
UG3 · FY2023 · DA
Opioid/benzodiazepine polydrug abuse: Integrating research on mechanisms, treatment and policies$606,796
R33 · FY2023 · DA · contact PI
Planning a Multi-Level Intervention to Reduce Substance Use Stigma in HIV Prevention and Care$222,216
R34 · FY2023 · DA
Opioid/benzodiazepine polydrug abuse: Integrating research on mechanisms, treatment and policies$606,796
R33 · FY2022 · DA · contact PI
Planning a Multi-Level Intervention to Reduce Substance Use Stigma in HIV Prevention and Care$232,141
R34 · FY2022 · DA
Opioid/benzodiazepine polydrug abuse: Integrating research on mechanisms, treatment and policies$655,159
R33 · FY2021 · DA · contact PI
Planning a Multi-Level Intervention to Reduce Substance Use Stigma in HIV Prevention and Care$229,670
R34 · FY2021 · DA
Dual-orexin antagonism as a mechanism for improving sleep and drug abstinence in opioid use disorder$4,021,723
U01 · FY2019 · HL · contact PI
Biobehavioral Studies of Opioid Seeking: Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence$512,408
R01 · FY2019 · DA · contact PI
Opioid/benzodiazepine polydrug abuse: Integrating research on mechanisms, treatment and policies$213,431
R21 · FY2019 · DA · contact PI
Biobehavioral Studies of Opioid Seeking: Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence$574,049
R01 · FY2018 · DA · contact PI
Opioid/benzodiazepine polydrug abuse: Integrating research on mechanisms, treatment and policies$203,023
R21 · FY2018 · DA · contact PI
Biobehavioral Studies of Opioid Seeking: Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence$575,786
R01 · FY2017 · DA · contact PI
Biobehavioral Studies of Opioid Seeking: Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence$617,480
R01 · FY2016 · DA · contact PI
Biobehavioral Studies of Opioid Seeking Behavior$353,395
R01 · FY2014 · DA · contact PI
Behavioral Economic Analysis of Medical Marijuana Use in HIV+ Patients$472,798
R01 · FY2013 · DA · contact PI
Biobehavioral Studies of Opioid Seeking Behavior$9,720
R01 · FY2013 · DA · contact PI
Development and Use of rtfMRI for Self-control of Nicotine Craving$533,133
R33 · FY2012 · DA
Behavioral Economic Analysis of Medical Marijuana Use in HIV+ Patients$500,925
R01 · FY2012 · DA · contact PI
Biobehavioral Studies of Opioid Seeking Behavior$368,203
R01 · FY2012 · DA · contact PI
Development and Use of rtfMRI for Self-control of Nicotine Craving$550,907
R33 · FY2011 · DA
Behavioral Economic Analysis of Medical Marijuana Use in HIV+ Patients$526,837
R01 · FY2011 · DA · contact PI
Biobehavioral Studies of Opioid Seeking Behavior$378,625
R01 · FY2011 · DA · contact PI
Integrated Substance use and Physical Health Intervention for Recovery (INSPIRE)$0
H79 · FY2011 · SU · contact PI
Human Laboratory Model of Cocaine Treatment: Behavioral Economic Analysis$697,526
R01 · FY2010 · DA · contact PI
Development and Use of rtfMRI for Self-control of Nicotine Craving$562,673
R33 · FY2010 · DA
Integrated Substance use and Physical Health Intervention for Recovery (INSPIRE)$0
H79 · FY2010 · SU · contact PI
Human Laboratory Model of Cocaine Treatment: Behavioral Economic Analysis$655,974
R01 · FY2009 · DA · contact PI
Reducing Cocaine/Heroin Abuse with SR-Amphetamine and Buprenorphine$325,811
R01 · FY2009 · DA · contact PI
Development and Use of rtfMRI for Self-control of Nicotine Craving$276,462
R21 · FY2009 · DA
Integrated Substance use and Physical Health Intervention for Recovery (INSPIRE)$0
H79 · FY2009 · SU · contact PI
Development and Use of rtfMRI for Self-control of Nicotine Craving$288,231
R21 · FY2008 · DA
Integrated Substance use and Physical Health Intervention for Recovery (INSPIRE)$0
H79 · FY2008 · SU · contact PI
Biobehavioral Studies of Opioid Drug Seeking Behavior$364,853
R01 · FY2007 · DA · contact PI
Reducing Cocaine/Heroin Abuse with SR-Amphetamine and Buprenorphine$321,427
R01 · FY2007 · DA · contact PI
Biobehavioral Studies of Opioid Drug Seeking Behavior$444,969
R01 · FY2006 · DA · contact PI
Reducing Cocaine/Heroin Abuse with SR-Amphetamine and Buprenorphine$333,073
R01 · FY2006 · DA · contact PI
Biobehavioral Studies of Opioid Drug Seeking Behavior$433,344
R01 · FY2005 · DA
Biobehavioral Studies of Opioid Drug Seeking Behavior$383,313
R01 · FY2004 · DA
Biobehavioral Studies of Opioid Drug Seeking Behavior$52,738
R01 · FY2004 · DA
Biobehavioral Studies of Opioid Drug Seeking Behavior$395,960
R01 · FY2003 · DA
BEHAVIORAL STUDIES WITH METHADONE CLIENTS$103,497
R29 · FY2001 · DA
BEHAVIORAL STUDIES WITH METHADONE CLIENTS$104,097
R29 · FY2000 · DA